Oren Livnat
Stock Analyst at HC Wainwright & Co.
(3.09)
# 1,319
Out of 4,761 analysts
140
Total ratings
42.36%
Success rate
1.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Oren Livnat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GRCE Grace Therapeutics | Reiterates: Buy | $12 | $3.29 | +264.74% | 1 | Feb 18, 2025 | |
| AVDL Avadel Pharmaceuticals | Reiterates: Buy | $25 → $21 | $8.41 | +149.70% | 15 | Jan 10, 2025 | |
| COLL Collegium Pharmaceutical | Reiterates: Buy | $50 | $29.13 | +71.64% | 9 | Jan 10, 2025 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $6 → $7.5 | $4.60 | +63.04% | 5 | Dec 13, 2024 | |
| PCRX Pacira BioSciences | Reiterates: Buy | $39 | $25.16 | +55.01% | 18 | Dec 4, 2024 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Buy | $200 | $136.01 | +47.05% | 16 | Nov 22, 2024 | |
| ZVRA Zevra Therapeutics | Reiterates: Buy | $20 | $7.68 | +160.42% | 8 | Nov 20, 2024 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $6 → $6.6 | $3.75 | +76.00% | 10 | Nov 11, 2024 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $94 | $57.94 | +62.24% | 11 | Nov 11, 2024 | |
| VRCA Verrica Pharmaceuticals | Downgrades: Neutral | n/a | $0.74 | - | 11 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.97 | - | 13 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $57 → $61 | $47.84 | +27.51% | 8 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7.5 | $5.76 | +30.21% | 6 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $8 | $1.07 | +647.66% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $60 | $3.38 | +1,660.36% | 5 | Aug 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $252 → $198 | $2.74 | +7,126.28% | 2 | May 7, 2021 |
Grace Therapeutics
Feb 18, 2025
Reiterates: Buy
Price Target: $12
Current: $3.29
Upside: +264.74%
Avadel Pharmaceuticals
Jan 10, 2025
Reiterates: Buy
Price Target: $25 → $21
Current: $8.41
Upside: +149.70%
Collegium Pharmaceutical
Jan 10, 2025
Reiterates: Buy
Price Target: $50
Current: $29.13
Upside: +71.64%
Trevi Therapeutics
Dec 13, 2024
Reiterates: Buy
Price Target: $6 → $7.5
Current: $4.60
Upside: +63.04%
Pacira BioSciences
Dec 4, 2024
Reiterates: Buy
Price Target: $39
Current: $25.16
Upside: +55.01%
Jazz Pharmaceuticals
Nov 22, 2024
Reiterates: Buy
Price Target: $200
Current: $136.01
Upside: +47.05%
Zevra Therapeutics
Nov 20, 2024
Reiterates: Buy
Price Target: $20
Current: $7.68
Upside: +160.42%
Xeris Biopharma Holdings
Nov 11, 2024
Maintains: Buy
Price Target: $6 → $6.6
Current: $3.75
Upside: +76.00%
ANI Pharmaceuticals
Nov 11, 2024
Reiterates: Buy
Price Target: $94
Current: $57.94
Upside: +62.24%
Verrica Pharmaceuticals
Nov 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.74
Upside: -
Jun 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.97
Upside: -
May 13, 2024
Maintains: Buy
Price Target: $57 → $61
Current: $47.84
Upside: +27.51%
Jan 4, 2024
Reiterates: Buy
Price Target: $7.5
Current: $5.76
Upside: +30.21%
May 13, 2022
Maintains: Buy
Price Target: $14 → $8
Current: $1.07
Upside: +647.66%
Aug 26, 2021
Maintains: Buy
Price Target: $43 → $60
Current: $3.38
Upside: +1,660.36%
May 7, 2021
Maintains: Buy
Price Target: $252 → $198
Current: $2.74
Upside: +7,126.28%